VSTM as of Nov 1 · 14:00 ET
VSTMNasdaqPharmaceutical Preparations

Verastem, Inc. · Brief

Next report

2 days

Nov 3 · before openest.Q3 FY26

Expected move

Inputs

Implied vs realized

6 reportsHistory
0 of 6≥ implied
avg implied
±39.3%
avg realized
±10.8%
Aug 8 '22±46.4%▲+7.56%×0.16
Feb 2 '23±48.6%▲+8.65%×0.18
Jan 13 '25±10.2%▼−6.81%×0.67
Q3 FY25±46.6%▼−20.10%×0.43
Q1 FY26±51.5%▲+7.78%×0.15
Q2 FY26±32.6%▲+14.04%×0.43
quarterimplied−55%0+55%realized×
Q2 FY26±32.6%▲+14.04%×0.43
Q1 FY26±51.5%▲+7.78%×0.15
Q3 FY25±46.6%▼−20.10%×0.43
Jan '25±10.2%▼−6.81%×0.67
Feb '23±48.6%▲+8.65%×0.18
Aug '22±46.4%▲+7.56%×0.16
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 3 report · est.

Bull2 of 3

+30.31%ten largest reporting managers increasing their reported shares over the latest quarter13F · Jun 30 '26
6disclosed supplier and customer ties named in SEC filingsSEC filings

Bear2 of 3

6 of 6recent reports with moves coming in under the options implied rangeEarnings history
3 of 24several of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

VSTM report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 21impliedImplied move: ±13.2% into Nov 3 earnings (Oct 21 close).Source
Oct 14haltTrading halt: 09:42 ET, resumed 09:47 ET.Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.